Latest News about REGN
Recent news which mentions REGN
Better Buy: CRISPR vs. Intellia
January 03, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
From Benzinga
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
From Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
December 16, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
From Benzinga
2 No-Brainer Healthcare Stocks to Buy Right Now
December 13, 2021
From Motley Fool
Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients
December 09, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
From Benzinga
Vir, GSK’s COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasma
December 07, 2021
From MarketWatch
2 Big Stock Bets That Are Insiders Are Buying Now
December 06, 2021
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
From Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
From Benzinga
Regeneron: Surfing on Covid, With More Under the Surface
December 02, 2021
From InvestorPlace
Why Are Stocks Down Today? 4 Things to Know.
November 30, 2021
From InvestorPlace
HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off
November 30, 2021
Tickers
REGN
From Benzinga
7 Drug Stocks to Buy Now While They’re Still on Sale
November 30, 2021
From InvestorPlace
From MarketWatch
WHO urges calm approach to omicron variant of COVID, warns travel restrictions may undermine surveillance and tracking
November 30, 2021
From MarketWatch
Retail Stocks Trading Lower on Weaker Black Friday Numbers
November 30, 2021
From Benzinga
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
November 30, 2021
From Benzinga
JPMorgan’s S&P 500 forecast for 2022 is among the most bullish on Wall Street. Here’s the biggest risk it sees for stocks.
November 30, 2021
From MarketWatch
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
November 29, 2021
From InvestorPlace
From Benzinga
Merck stock dives after Citi downgrades on ‘high probability’ that HIV treatment will be abandoned
November 29, 2021
From MarketWatch
Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
November 22, 2021
From Benzinga
From Motley Fool
Is Merck Stock a Buy?
November 20, 2021
From Motley Fool
Why Connect Biopharma Stock Is Crashing Today
November 19, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.